Detalhe da pesquisa
1.
Everolimus plus exemestane as first-line therapy in HRâº, HER2â» advanced breast cancer in BOLERO-2.
Breast Cancer Res Treat
; 143(3): 459-67, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24362951
2.
Practical management of everolimus-related toxicities in patients with advanced solid tumors.
Onkologie
; 36(5): 295-302, 2013.
Artigo
em Inglês
| MEDLINE | ID: mdl-23689226
3.
Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany.
Breast
; 54: 88-95, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32956934
4.
Therapy Landscape in Patients with Metastatic HER2-Positive Breast Cancer: Data from the PRAEGNANT Real-World Breast Cancer Registry.
Cancers (Basel)
; 11(1)2018 Dec 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-30577662
5.
Treatment landscape of advanced breast cancer patients with hormone receptor positive HER2 negative tumors - Data from the German PRAEGNANT breast cancer registry.
Breast
; 37: 42-51, 2018 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-29100043
6.
A randomised trial of goserelin versus control after adjuvant, risk-adapted chemotherapy in premenopausal patients with primary breast cancer - GABG-IV B-93.
Eur J Cancer
; 43(16): 2351-8, 2007 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-17897821
7.
Tamoxifen versus control after adjuvant, risk-adapted chemotherapy in postmenopausal, receptor-negative patients with breast cancer: a randomized trial (GABG-IV D-93)--the German Adjuvant Breast Cancer Group.
J Clin Oncol
; 23(31): 7842-8, 2005 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-16258087
8.
CMF versus goserelin as adjuvant therapy for node-negative, hormone-receptor-positive breast cancer in premenopausal patients: a randomised trial (GABG trial IV-A-93).
Eur J Cancer
; 42(12): 1780-8, 2006 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-16765589
9.
First-line Bevacizumab-containing Therapy for HER2-negative Metastatic Breast Cancer: Final Results from a Prospective German Study.
Anticancer Res
; 36(3): 967-74, 2016 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-26976985
10.
Corrigendum to "Initial experience with CDK4/6 inhibitor-based therapies compared to antihormone monotherapies in routine clinical use in patients with hormone receptor positive, HER2 negative breast cancer - Data from the PRAEGNANT research network for the first 2 years of drug availability in Germany".
Breast
; 55: 138-139, 2021 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-33413981
11.
Effect of everolimus on bone marker levels and progressive disease in bone in BOLERO-2.
J Natl Cancer Inst
; 105(9): 654-63, 2013 May 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-23425564
12.
Only grading has independent impact on breast cancer survival after adjustment for pathological response to preoperative chemotherapy.
Anticancer Drugs
; 15(2): 127-35, 2004 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-15075668